FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2600261757> ?p ?o ?g. }

• W2600261757 endingPage "2354" @default.
• W2600261757 startingPage "2347" @default.
• W2600261757 abstract "Therapy-related acute promyelocytic leukemia (t-APL) is relatively rare, with limited data on outcome after treatment with arsenic trioxide (ATO) compared to standard intensive chemotherapy (CTX). We evaluated 103 adult t-APL patients undergoing treatment with all-trans retinoic acid (ATRA) alone (n=7) or in combination with ATO (n=24), CTX (n=53), or both (n=19). Complete remissions were achieved after induction therapy in 57% with ATRA, 100% with ATO/ATRA, 78% with CTX/ATRA, and 95% with CTX/ATO/ATRA. Early death rates were 43% for ATRA, 0% for ATO/ATRA, 12% for CTX/ATRA and 5% for CTX/ATO/ATRA. Three patients relapsed, two developed therapy-related acute myeloid leukemia and 13 died in remission including seven patients with recurrence of the prior malignancy. Median follow-up for survival was 3.7 years. None of the patients treated with ATRA alone survived beyond one year. Event-free survival was significantly higher after ATO-based therapy (95%, 95% CI, 82–99%) as compared to CTX/ATRA (78%, 95% CI, 64–87%; P=0.042), if deaths due to recurrence of the prior malignancy were censored. The estimated 2-year overall survival in intensively treated patients was 88% (95% CI, 80–93%) without difference according to treatment (P=0.47). ATO when added to ATRA or CTX/ATRA is feasible and leads to better outcomes as compared to CTX/ATRA in t-APL." @default.
• W2600261757 created "2017-04-07" @default.
• W2600261757 creator A5001124933 @default.
• W2600261757 creator A5006122560 @default.
• W2600261757 creator A5011742331 @default.
• W2600261757 creator A5012395020 @default.
• W2600261757 creator A5013626352 @default.
• W2600261757 creator A5013645809 @default.
• W2600261757 creator A5017002895 @default.
• W2600261757 creator A5018576827 @default.
• W2600261757 creator A5026359397 @default.
• W2600261757 creator A5029575769 @default.
• W2600261757 creator A5035489508 @default.
• W2600261757 creator A5036912140 @default.
• W2600261757 creator A5046387225 @default.
• W2600261757 creator A5049910941 @default.
• W2600261757 creator A5051026089 @default.
• W2600261757 creator A5053949970 @default.
• W2600261757 creator A5054654885 @default.
• W2600261757 creator A5057920623 @default.
• W2600261757 creator A5060811966 @default.
• W2600261757 creator A5064262892 @default.
• W2600261757 creator A5064374340 @default.
• W2600261757 creator A5067065015 @default.
• W2600261757 creator A5071757596 @default.
• W2600261757 creator A5078452627 @default.
• W2600261757 creator A5079124367 @default.
• W2600261757 creator A5080857567 @default.
• W2600261757 creator A5086903284 @default.
• W2600261757 creator A5087346637 @default.
• W2600261757 creator A5089075443 @default.
• W2600261757 creator A5089694123 @default.
• W2600261757 date "2017-03-21" @default.
• W2600261757 modified "2023-10-15" @default.
• W2600261757 title "Characteristics and outcome of patients with therapy-related acute promyelocytic leukemia front-line treated with or without arsenic trioxide" @default.
• W2600261757 cites W1481500489 @default.
• W2600261757 cites W1521479021 @default.
• W2600261757 cites W1554600230 @default.
• W2600261757 cites W1926757141 @default.
• W2600261757 cites W1948328750 @default.
• W2600261757 cites W1965141571 @default.
• W2600261757 cites W1970521293 @default.
• W2600261757 cites W1971056717 @default.
• W2600261757 cites W1971211622 @default.
• W2600261757 cites W1977747092 @default.
• W2600261757 cites W1990312495 @default.
• W2600261757 cites W1994791499 @default.
• W2600261757 cites W1996750522 @default.
• W2600261757 cites W2004294093 @default.
• W2600261757 cites W2005054491 @default.
• W2600261757 cites W2005246349 @default.
• W2600261757 cites W2016132084 @default.
• W2600261757 cites W2047008143 @default.
• W2600261757 cites W2057165314 @default.
• W2600261757 cites W2065293555 @default.
• W2600261757 cites W2067578884 @default.
• W2600261757 cites W2074453573 @default.
• W2600261757 cites W2084219839 @default.
• W2600261757 cites W2084414912 @default.
• W2600261757 cites W2085251563 @default.
• W2600261757 cites W2092223900 @default.
• W2600261757 cites W2096318892 @default.
• W2600261757 cites W2098494369 @default.
• W2600261757 cites W2105404731 @default.
• W2600261757 cites W2120811574 @default.
• W2600261757 cites W2129338773 @default.
• W2600261757 cites W2132912591 @default.
• W2600261757 cites W2137583404 @default.
• W2600261757 cites W2138630072 @default.
• W2600261757 cites W2146073546 @default.
• W2600261757 cites W2150113701 @default.
• W2600261757 cites W2152200313 @default.
• W2600261757 cites W2159507916 @default.
• W2600261757 cites W2161249351 @default.
• W2600261757 cites W2253167439 @default.
• W2600261757 cites W2256214571 @default.
• W2600261757 cites W2269450671 @default.
• W2600261757 cites W2327237185 @default.
• W2600261757 cites W2329310651 @default.
• W2600261757 cites W2344085448 @default.
• W2600261757 cites W2407345634 @default.
• W2600261757 cites W2474389367 @default.
• W2600261757 cites W2557652172 @default.
• W2600261757 cites W2558446569 @default.
• W2600261757 cites W2561289538 @default.
• W2600261757 cites W4239856335 @default.
• W2600261757 cites W4293241248 @default.
• W2600261757 cites W4376595466 @default.
• W2600261757 cites W2002494533 @default.
• W2600261757 doi "https://doi.org/10.1038/leu.2017.92" @default.
• W2600261757 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6037311" @default.
• W2600261757 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/28322237" @default.
• W2600261757 hasPublicationYear "2017" @default.
• W2600261757 type Work @default.
• W2600261757 sameAs 2600261757 @default.
• W2600261757 citedByCount "32" @default.
• W2600261757 countsByYear W26002617572017 @default.
• W2600261757 countsByYear W26002617572018 @default.

• next